查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1859760

全球基因組學市場預測（至2032年）：依產品、功能、交付模式、技術、應用、最終用戶和地區進行分析

Genomics Market Forecasts to 2032 - Global Analysis By Product (Instruments, Consumables and Software & Services), Function, Delivery Model, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2025 年，全球基因組學市場規模將達到 443 億美元，到 2032 年將達到 1,291 億美元，預測期內複合年成長率為 16.5%。

基因組學是分子生物學的一個分支，專注於基因組（生物體內完整的DNA序列）的結構、功能、演化、定位和編輯。它分析基因及其相互作用，以了解生物過程、疾病機制和遺傳變異。基因組學在個人化醫療、農業、生物技術和環境科學中發揮著至關重要的作用。定序、生物資訊學和基因編輯等技術使研究人員能夠識別遺傳標記、開發標靶治療並改良作物性狀。透過破解生命的遺傳藍圖，基因組學推動了醫療保健和整個科學領域的創新，並為遺傳學、健康風險和演化生物學提供了新的見解。

對個人化醫療的需求日益成長

個人化醫療的日益普及是基因組學市場發展的關鍵驅動力。透過根據個別基因譜量身訂做治療方案，醫療服務提供者可以改善治療效果並減少副作用。基因組學能夠實現精準診斷、標靶治療和預測風險評估，尤其是在腫瘤學、心臟病學和罕見疾病領域。隨著病患和醫療服務提供者對個人化醫療服務的需求不斷成長，基因組檢測和數據分析的需求也日益增加，這得益於定序技術的進步以及與電子健康記錄的整合。

基因組設備和服務高成本

儘管基因組學市場具有巨大的變革潛力，但仍面臨顯著的成本限制。定序平台、試劑和生物資訊工具的高昂成本限制了其普及，尤其是在資源匱乏的地區。此外，對熟練人員和基礎設施的需求也增加了營運成本。這些經濟障礙阻礙了基因組學在臨床和農業領域的廣泛應用。雖然價格正在逐步下降，但對於小規模實驗室和新興市場而言，負擔能力仍然是一個挑戰，因此需要可擴展的解決方案和官民合作關係來在全球擴展基因組學能力。

定序技術的進步

測序方法的創新帶來了巨大的市場機會。次世代定序(NGS) 和新興平台能夠提供更快、更準確、更有經濟效率的基因組分析。這些進步使得基因組分析在診斷、藥物研發和群體基因組學等領域擁有廣泛的應用前景。隨著定序分析的普及，研究人員和臨床醫生將能夠更精確地研究複雜的基因交互作用和罕見突變。自動化和數據解讀技術的持續進步將進一步強化基因組學在個人化醫療和全球健康計畫中的作用。

資料隱私和倫理問題

資料隱私和倫理挑戰對市場構成重大威脅。處理敏感的基因資訊引發了人們對知情同意、資料安全和濫用的擔憂。患者可能不願意在沒有明確保障措施的情況下共用其基因組數據，尤其是在直接面對消費者的檢測中。法律規範因地區而異，這使得合規性和跨境研究更加複雜。圍繞基因編輯、歧視和基因數據所有權的倫理困境將進一步加劇公眾的關注。解決這些問題需要透明的政策、強大的網路安全和倫理監督，以維護公眾信任。

新冠疫情的影響：

新冠疫情加速了基因組學研究和應用，尤其是在病毒序列測定和疫苗研發方面。基因組監測在追蹤病毒變異和指導公共衛生應對措施方面發揮了關鍵作用。此次危機也凸顯了快速診斷和個人化治療策略的重要性。儘管初期中斷影響了供應鏈和研究進度，但對基因組學基礎設施的長期投資卻大幅成長。疫情凸顯了基因組數據在感染疾病管理中的價值，並加強了其在常規醫療保健和全球緊急準備工作中的應用。

預計在預測期內，微陣列細分市場將成為最大的細分市場。

由於微陣列技術在基因表現分析、基因型鑒定和生物標記發現等領域的廣泛應用，預計在預測期內，微陣列技術將佔據最大的市場佔有率。微陣列技術提供高通量分析，並為大規模研究提供了一種經濟高效的解決方案。其能夠同時檢測數千個基因，使其在研究、診斷和藥物基因組學領域中具有重要價值。隨著對個人化醫療和疾病風險評估需求的不斷成長，微陣列技術仍然是學術機構、臨床實驗室和生物技術公司尋求可靠基因組學見解的首選工具。

預計法醫學基因組學領域在預測期內將實現最高的複合年成長率

預計在預測期內，法醫學基因組學領域將呈現最高的成長率，因為DNA定序和生物資訊學的進步正在徹底改變刑事調查、親子鑑定和災難受害者身分識別。基因組分析工具能夠對劣化或有限的樣本進行精確分析，從而提高法醫學案件的準確性和解析度。對快速、攜帶式檢測解決方案以及與國家資料庫整合的需求不斷成長，進一步推動了該技術的應用。隨著法律體系越來越接受基因組證據，法醫學基因組學有望在執法機關和司法領域中迅速發展。

最大佔有率地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。這主要得益於該地區人口的快速成長、醫療保健投資的增加以及人們對基因檢測日益成長的認知，這些因素共同推動了該地區的需求。中國、印度和日本等國家正透過政府舉措和私部門合作來促進基因組研究。不斷擴大的生物技術基礎、有利的法規環境以及人們對個人化醫療日益成長的興趣，都有助於鞏固亞太地區的市場主導地位。憑藉強大的學術機構和新興新興企業，亞太地區在基因組創新和普及方面處於領先地位。

複合年成長率最高的地區：

由於北美地區擁有強大的研究基礎設施、高額的醫療保健支出以及對先進技術的早期應用，預計該地區在預測期內將呈現最高的複合年成長率。該地區在精準醫療和生物資訊學領域的領先地位正在推動市場的快速成長。政府的資金支持、卓越的學術水平和強大的產業實力正在推動診斷、治療和農業領域的創新。監管支持和公眾意識的提高也進一步促進了技術的普及應用。隨著基因組學日益成為醫療保健和生命科學不可或缺的一部分，北美將繼續引領全球擴張的腳步。

免費客製化服務：

訂閱本報告的用戶可享有以下免費客製化服務之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球基因體學市場（依產品分類）

  • 裝置
    • 音序器和放大器
    • 樣品製備設備
    • DNA/RNA分析儀
  • 消耗品
    • 試劑和試劑盒
    • 面板和晶片
  • 軟體和服務
    • 生物資訊軟體
    • 數據分析服務
    • 雲端基礎的解決方案
    • 維護和支援服務

6. 全球基因體學市場按功能分類

  • 基因組序列分析
  • 表觀基因分析
  • 基因表現分析
  • 基因型鑒定

7. 全球基因體學市場依交付模式分類

  • 本地部署
  • 基於網路的
  • 雲端基礎的

8. 全球基因體學市場（依技術分類）

  • 定序
    • 次世代定序（NGS）
    • 桑格定序
    • 第三代定序
  • PCR
    • 定量PCR
    • dPCR
  • 微陣列
  • CRISPR
  • 表觀基因

9. 全球基因體學市場（按應用分類）

  • 診斷
    • 癌症診斷
    • 罕見疾病診斷
    • 感染疾病診斷
  • 藥物發現與開發
  • 法醫學基因組學
  • 精準醫療
  • 農業和動物研究
  • 其他用途

第10章：全球基因體學市場（以最終用戶分類）

  • 醫院和診所
  • 診斷檢查室
  • 研究和學術機構
  • 製藥和生物技術公司
  • 合約研究組織（CRO）

第11章：全球基因組學市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第13章：企業概況

  • Illumina
  • Eurofins Scientific
  • Thermo Fisher Scientific
  • GenScript Biotech
  • BGI Genomics
  • Intellia Therapeutics
  • Agilent Technologies
  • CRISPR Therapeutics
  • Roche
  • Oxford Nanopore Technologies
  • Bio-Rad Laboratories
  • Pacific Biosciences
  • QIAGEN
  • 10x Genomics
  • Natera
Product Code: SMRC31984

According to Stratistics MRC, the Global Genomics Market is accounted for $44.3 billion in 2025 and is expected to reach $129.1 billion by 2032 growing at a CAGR of 16.5% during the forecast period. Genomics is the branch of molecular biology focused on the structure, function, evolution, mapping, and editing of genomes-the complete set of DNA within an organism. It involves analyzing genes and their interactions to understand biological processes, disease mechanisms, and genetic variation. Genomics plays a vital role in personalized medicine, agriculture, biotechnology, and environmental science. Techniques such as sequencing, bioinformatics, and gene editing enable researchers to identify genetic markers, develop targeted therapies, and improve crop traits. By decoding the genetic blueprint of life, genomics drives innovation across healthcare and science, offering insights into heredity, health risks, and evolutionary biology.

Market Dynamics:

Driver:

Rising Demand for Personalized Medicine

The growing emphasis on personalized medicine is a major driver of the genomics market. By tailoring treatments to individual genetic profiles, healthcare providers can improve outcomes and reduce adverse reactions. Genomics enables precise diagnosis, targeted therapies, and predictive risk assessments, especially in oncology, cardiology, and rare diseases. As patients and providers seek more customized care, demand for genomic testing and data analytics continues to rise, supported by advances in sequencing technologies and integration with electronic health records.

Restraint:

High Cost of Genomic Equipment and Services

Despite its transformative potential, the genomics market faces significant cost-related restraints. High expenses for sequencing platforms, reagents, and bioinformatics tools limit accessibility, particularly in low-resource settings. Additionally, the need for skilled personnel and infrastructure adds to operational costs. These financial barriers hinder widespread adoption in clinical and agricultural applications. While prices are gradually declining, affordability remains a challenge for small labs and emerging markets, necessitating scalable solutions and public-private partnerships to expand genomic capabilities globally.

Opportunity:

Advancements in Sequencing Technologies

Technological innovation in sequencing methods presents a major opportunity for the market. Next-generation sequencing (NGS) and emerging platforms offer faster, more accurate, and cost-effective genome analysis. These advancements enable broader applications in diagnostics, drug development, and population genomics. As sequencing becomes more accessible, researchers and clinicians can explore complex genetic interactions and rare variants with greater precision. Continued progress in automation and data interpretation will further enhance genomics' role in personalized medicine and global health initiatives.

Threat:

Data Privacy and Ethical Concerns

Data privacy and ethical challenges pose a significant threat to the market. Handling sensitive genetic information raises concerns about consent, data security, and misuse. Patients may be reluctant to share genomic data without clear safeguards, especially in direct-to-consumer testing. Regulatory frameworks vary across regions, complicating compliance and cross-border research. Ethical dilemmas around gene editing, discrimination, and ownership of genetic data further intensify scrutiny. Addressing these issues requires transparent policies, robust cybersecurity, and ethical oversight to maintain public trust.

Covid-19 Impact:

The COVID-19 pandemic accelerated genomics research and applications, particularly in viral sequencing and vaccine development. Genomic surveillance played a critical role in tracking mutations and guiding public health responses. The crisis also highlighted the importance of rapid diagnostics and personalized treatment strategies. While initial disruptions affected supply chains and research timelines, long-term investment in genomics infrastructure surged. The pandemic underscored the value of genomic data in managing infectious diseases and reinforced its integration into routine healthcare and global preparedness efforts.

The microarrays segment is expected to be the largest during the forecast period

The microarrays segment is expected to account for the largest market share during the forecast period, due to its widespread use in gene expression profiling, genotyping, and biomarker discovery. Microarrays offer high-throughput analysis and cost-effective solutions for large-scale studies. Their ability to simultaneously examine thousands of genes makes them valuable in research, diagnostics, and pharmacogenomics. As demand grows for personalized medicine and disease risk assessment, microarrays remain a preferred tool for academic institutions, clinical laboratories, and biotech companies seeking reliable genomic insights.

The forensic genomics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the forensic genomics segment is predicted to witness the highest growth rate, due to advances in DNA sequencing and bioinformatics are revolutionizing criminal investigations, paternity testing, and disaster victim identification. Genomic tools enable precise analysis of degraded or limited samples, improving accuracy and resolution in forensic cases. Growing demand for rapid, portable testing solutions and integration with national databases further drives adoption. As legal systems embrace genomic evidence, forensic genomics is poised for rapid expansion across law enforcement and judicial applications.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid population growth, increasing healthcare investments, and rising awareness of genetic testing fuel regional demand. Countries like China, India, and Japan are advancing genomics research through government initiatives and private sector collaboration. Expanding biotech hubs, favorable regulatory environments, and growing interest in personalized medicine contribute to market dominance. With a strong base of academic institutions and emerging startups, Asia Pacific leads in genomic innovation and accessibility.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of advanced technologies. The region's leadership in precision medicine and bioinformatics supports rapid market growth. Government funding, academic excellence and strong industry presence foster innovation across diagnostics, therapeutics, and agriculture. Regulatory support and public awareness further enhance adoption. As genomics becomes integral to healthcare and life sciences, North America continues to set the pace for global expansion.

Key players in the market

Some of the key players in Genomics Market include Illumina, Eurofins Scientific, Thermo Fisher Scientific, GenScript Biotech, BGI Genomics, Intellia Therapeutics, Agilent Technologies, CRISPR Therapeutics, Roche, Oxford Nanopore Technologies, Bio-Rad Laboratories, Pacific Biosciences, QIAGEN, 10x Genomics, and Natera.

Key Developments:

In July 2025, Thermo Fisher Scientific has expanded its strategic partnership with Sanofi by acquiring Sanofi's state-of-the-art sterile fill-finish and packaging facility in Ridgefield, New Jersey. This acquisition enhances Thermo Fisher's U.S. manufacturing capabilities, enabling the production of critical medicines for Sanofi and meeting the growing demand from pharmaceutical and biotech customers.

In May 2025, RoosterBio and Thermo Fisher Scientific have announced collaboration aimed at advancing the development and manufacturing of cell and exosome therapies for degenerative diseases. This partnership combines RoosterBio's expertise in human mesenchymal stem/stromal cells (hMSCs) and exosome technologies with Thermo Fisher's global contract manufacturing capabilities.

Products Covered:

  • Instruments
  • Consumables
  • Software & Services

Functions Covered:

  • Genome Sequencing
  • Epigenomic Analysis
  • Gene Expression Profiling
  • Genotyping

Delivery Models Covered:

  • On-Premise
  • Web-Based
  • Cloud-Based

Technologies Covered:

  • Sequencing
  • PCR
  • Microarrays
  • CRISPR
  • Epigenomics

Applications Covered:

  • Diagnostics
  • Drug Discovery & Development
  • Forensic Genomics
  • Precision Medicine
  • Agriculture & Animal Research
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genomics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Sequencers & Amplifiers
    • 5.2.2 Sample Preparation Instruments
    • 5.2.3 DNA/RNA Analyzers
  • 5.3 Consumables
    • 5.3.1 Reagents & Kits
    • 5.3.2 Panels & Chips
  • 5.4 Software & Services
    • 5.4.1 Bioinformatics Software
    • 5.4.2 Data Analysis Services
    • 5.4.3 Cloud-based Solutions
    • 5.4.4 Maintenance & Support Services

6 Global Genomics Market, By Function

  • 6.1 Introduction
  • 6.2 Genome Sequencing
  • 6.3 Epigenomic Analysis
  • 6.4 Gene Expression Profiling
  • 6.5 Genotyping

7 Global Genomics Market, By Delivery Model

  • 7.1 Introduction
  • 7.2 On-Premise
  • 7.3 Web-Based
  • 7.4 Cloud-Based

8 Global Genomics Market, By Technology

  • 8.1 Introduction
  • 8.2 Sequencing
    • 8.2.1 Next-Generation Sequencing (NGS)
    • 8.2.2 Sanger Sequencing
    • 8.2.3 Third-Generation Sequencing
  • 8.3 PCR
    • 8.3.1 qPCR
    • 8.3.2 dPCR
  • 8.4 Microarrays
  • 8.5 CRISPR
  • 8.6 Epigenomics

9 Global Genomics Market, By Application

  • 9.1 Introduction
  • 9.2 Diagnostics
    • 9.2.1 Cancer Diagnostics
    • 9.2.2 Rare Disease Diagnostics
    • 9.2.3 Infectious Disease Diagnostics
  • 9.3 Drug Discovery & Development
  • 9.4 Forensic Genomics
  • 9.5 Precision Medicine
  • 9.6 Agriculture & Animal Research
  • 9.7 Other Applications

10 Global Genomics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Diagnostic Laboratories
  • 10.4 Research & Academic Institutions
  • 10.5 Pharmaceutical & Biotechnology Companies
  • 10.6 Contract Research Organizations (CROs)

11 Global Genomics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Illumina
  • 13.2 Eurofins Scientific
  • 13.3 Thermo Fisher Scientific
  • 13.4 GenScript Biotech
  • 13.5 BGI Genomics
  • 13.6 Intellia Therapeutics
  • 13.7 Agilent Technologies
  • 13.8 CRISPR Therapeutics
  • 13.9 Roche
  • 13.10 Oxford Nanopore Technologies
  • 13.11 Bio-Rad Laboratories
  • 13.12 Pacific Biosciences
  • 13.13 QIAGEN
  • 13.14 10x Genomics
  • 13.15 Natera

List of Tables

  • Table 1 Global Genomics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Genomics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Genomics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Genomics Market Outlook, By Sequencers & Amplifiers (2024-2032) ($MN)
  • Table 5 Global Genomics Market Outlook, By Sample Preparation Instruments (2024-2032) ($MN)
  • Table 6 Global Genomics Market Outlook, By DNA/RNA Analyzers (2024-2032) ($MN)
  • Table 7 Global Genomics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Genomics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
  • Table 9 Global Genomics Market Outlook, By Panels & Chips (2024-2032) ($MN)
  • Table 10 Global Genomics Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 11 Global Genomics Market Outlook, By Bioinformatics Software (2024-2032) ($MN)
  • Table 12 Global Genomics Market Outlook, By Data Analysis Services (2024-2032) ($MN)
  • Table 13 Global Genomics Market Outlook, By Cloud-based Solutions (2024-2032) ($MN)
  • Table 14 Global Genomics Market Outlook, By Maintenance & Support Services (2024-2032) ($MN)
  • Table 15 Global Genomics Market Outlook, By Function (2024-2032) ($MN)
  • Table 16 Global Genomics Market Outlook, By Genome Sequencing (2024-2032) ($MN)
  • Table 17 Global Genomics Market Outlook, By Epigenomic Analysis (2024-2032) ($MN)
  • Table 18 Global Genomics Market Outlook, By Gene Expression Profiling (2024-2032) ($MN)
  • Table 19 Global Genomics Market Outlook, By Genotyping (2024-2032) ($MN)
  • Table 20 Global Genomics Market Outlook, By Delivery Model (2024-2032) ($MN)
  • Table 21 Global Genomics Market Outlook, By On-Premise (2024-2032) ($MN)
  • Table 22 Global Genomics Market Outlook, By Web-Based (2024-2032) ($MN)
  • Table 23 Global Genomics Market Outlook, By Cloud-Based (2024-2032) ($MN)
  • Table 24 Global Genomics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 25 Global Genomics Market Outlook, By Sequencing (2024-2032) ($MN)
  • Table 26 Global Genomics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 27 Global Genomics Market Outlook, By Sanger Sequencing (2024-2032) ($MN)
  • Table 28 Global Genomics Market Outlook, By Third-Generation Sequencing (2024-2032) ($MN)
  • Table 29 Global Genomics Market Outlook, By PCR (2024-2032) ($MN)
  • Table 30 Global Genomics Market Outlook, By qPCR (2024-2032) ($MN)
  • Table 31 Global Genomics Market Outlook, By dPCR (2024-2032) ($MN)
  • Table 32 Global Genomics Market Outlook, By Microarrays (2024-2032) ($MN)
  • Table 33 Global Genomics Market Outlook, By CRISPR (2024-2032) ($MN)
  • Table 34 Global Genomics Market Outlook, By Epigenomics (2024-2032) ($MN)
  • Table 35 Global Genomics Market Outlook, By Application (2024-2032) ($MN)
  • Table 36 Global Genomics Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 37 Global Genomics Market Outlook, By Cancer Diagnostics (2024-2032) ($MN)
  • Table 38 Global Genomics Market Outlook, By Rare Disease Diagnostics (2024-2032) ($MN)
  • Table 39 Global Genomics Market Outlook, By Infectious Disease Diagnostics (2024-2032) ($MN)
  • Table 40 Global Genomics Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
  • Table 41 Global Genomics Market Outlook, By Forensic Genomics (2024-2032) ($MN)
  • Table 42 Global Genomics Market Outlook, By Precision Medicine (2024-2032) ($MN)
  • Table 43 Global Genomics Market Outlook, By Agriculture & Animal Research (2024-2032) ($MN)
  • Table 44 Global Genomics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 45 Global Genomics Market Outlook, By End User (2024-2032) ($MN)
  • Table 46 Global Genomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 47 Global Genomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 48 Global Genomics Market Outlook, By Research & Academic Institutions (2024-2032) ($MN)
  • Table 49 Global Genomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 50 Global Genomics Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.